Success Metrics

Clinical Success Rate
89.4%

Based on 42 completed trials

Completion Rate
89%(42/47)
Active Trials
8(11%)
Results Posted
40%(17 trials)
Terminated
5(7%)

Phase Distribution

Ph not_applicable
14
19%
Ph early_phase_1
6
8%
Ph phase_1
9
12%
Ph phase_3
9
12%
Ph phase_4
13
18%
Ph phase_2
23
31%

Phase Distribution

15

Early Stage

23

Mid Stage

22

Late Stage

Phase Distribution74 total trials
Early Phase 1First-in-human
6(8.1%)
Phase 1Safety & dosage
9(12.2%)
Phase 2Efficacy & side effects
23(31.1%)
Phase 3Large-scale testing
9(12.2%)
Phase 4Post-market surveillance
13(17.6%)
N/ANon-phased studies
14(18.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

42 of 48 finished

Non-Completion Rate

12.5%

6 ended early

Currently Active

8

trials recruiting

Total Trials

74

all time

Status Distribution
Active(12)
Completed(42)
Terminated(6)
Other(14)

Detailed Status

Completed42
unknown14
Terminated5
Recruiting5
Active, not recruiting3
Enrolling by invitation2

Development Timeline

Analytics

Development Status

Total Trials
74
Active
8
Success Rate
89.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (8.1%)
Phase 19 (12.2%)
Phase 223 (31.1%)
Phase 39 (12.2%)
Phase 413 (17.6%)
N/A14 (18.9%)

Trials by Status

enrolling_by_invitation23%
not_yet_recruiting23%
active_not_recruiting34%
terminated57%
unknown1419%
recruiting57%
withdrawn11%
completed4257%

Recent Activity

Clinical Trials (74)

Showing 20 of 74 trialsScroll for more
NCT04481048Phase 2

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Completed
NCT04291066Phase 2

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

Completed
NCT04627922Phase 4

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

Completed
NCT04300920Phase 3

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

Completed
NCT05122559Phase 2

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Active Not Recruiting
NCT05986318Phase 2

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

Recruiting
NCT04381897Phase 2

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Not Yet Recruiting
NCT07391163Not Applicable

Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer

Completed
NCT03032601Not Applicable

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

Enrolling By Invitation
NCT03241732Not Applicable

PET-MRI in Chronic Traumatic Brain Injury (CTBI)

Enrolling By Invitation
NCT04920448Phase 2

N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE

Terminated
NCT02804594Phase 2

A Study of Oxidative Pathways in MS Fatigue

Completed
NCT06836128Phase 3

The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients

Recruiting
NCT04987775Early Phase 1

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

Recruiting
NCT05485558Phase 2

the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

Completed
NCT05686356Phase 2

A Pan-TB Regimen Targeting Host and Microbe

Active Not Recruiting
NCT01878669Phase 3

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention

Active Not Recruiting
NCT05309070Not Applicable

The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome

Completed
NCT04732000Phase 2

Oxidative Stress and Surgical Recovery

Completed
NCT06834711Not Applicable

Chlorhexidine Versus N-Asetil Sistein Irrigation in Mandibular Molar Teeth with Chronic Apical Periodontitis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
74